Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights Emergent BioSolutions, Chimerix and SIGA Technologies
by Zacks Equity Research
Emergent BioSolutions, Chimerix and SIGA Technologies have been included in this Analyst Blog.
Monkeypox Fears Drive Smallpox Antiviral Makers Higher
by Kinjel Shah
Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.
Implied Volatility Surging for Emergent Biosolutions (EBS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Emergent Biosolutions (EBS) stock based on the movements in the options market lately.
Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates
by Zacks Equity Research
The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
Emergent Biosolutions (EBS) Q1 Earnings Lag Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25% and 3.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 28th
by Zacks Equity Research
LAZR, EBS, and ROCK have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2022
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
by Zacks Equity Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 12.68% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study
by Zacks Equity Research
Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.
New Strong Sell Stocks for March 11th
by Zacks Equity Research
AVVIY, EBS, and NVEI have been added to the Zacks Rank #5 (Strong Sell) List on March 11, 2022.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
by Zacks Equity Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
by Zacks Equity Research
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
Endo (ENDP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Emergent (EBS) Begins Dosing in Study on Influenza Vaccine
by Zacks Equity Research
Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.
Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down
by Zacks Equity Research
Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment. Stock down in after-market trading.
Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -117.73% and -27.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Emergent Biosolutions (EBS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
by Zacks Equity Research
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
New Strong Sell Stocks for August 2nd
by Zacks Equity Research
ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
by Zacks Equity Research
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.
Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?